Drug lookup | Fillwise

ACEBUTOLOL HCL

6 general benefit · 3 not a benefit

Other products in the same Health Canada class (C07A, C07AB) — coverage varies; not interchangeable

Atenolol (Apo-Atenol): general benefit
Bisoprolol (Sandoz Bisoprolol Tablets): general benefit, Not a benefit
Metoprolol (Lopresor SR): general benefit, Not a benefit
Nebivolol (Bystolic): not a benefit
Nadolol (Corgard): general benefit, Not a benefit
Propranolol (Inderal-LA): general benefit, Not a benefit

3 more in the class list below

Apo-Acebutolol · DIN 02147602 · 100mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Apo-Acebutolol · DIN 02147602 Manufacturer: Apotex Inc.; listing date 1996-10-01 Daily cost (source): $0.3742 Health Canada: Marketed since 1995-12-31 · brand APO-ACEBUTOLOL · ATC C07AB04 ACEBUTOLOL · form Tablet · route Oral · ingredients ACEBUTOLOL (ACEBUTOLOL HYDROCHLORIDE) 100 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Acebutolol: Formulary list price $0.1871/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1871 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17826 · Verify on the e-Formulary ↗ (DIN 02147602)

Source record

DIN 02147602: Apo-Acebutolol Raw flags: chronicUseMed=Y, sec3=Y Item: 240400084; group id 272; item number 0562; lccId None; manufacturer id APX Source form: Tab; strength: 100mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1871; ministry $0.1871 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02147602 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17826

Interchangeable products

Sectral · DIN 01926543 · not recorded Teva-Acebutolol · DIN 02204517 · $0.1871

Shortage status: resolved shortage (ended 2023-12-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02147602

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Acebutolol · DIN 02204517 · 100mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Teva-Acebutolol · DIN 02204517 Manufacturer: Teva Canada Limited; listing date 1998-12-31 Daily cost (source): $0.3742 Health Canada: Marketed since 2011-01-25 · brand TEVA-ACEBUTOLOL · ATC C07AB04 ACEBUTOLOL · form Tablet · route Oral · ingredients ACEBUTOLOL (ACEBUTOLOL HYDROCHLORIDE) 100 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Teva-Acebutolol: Formulary list price $0.1871/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1871 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42996 · Verify on the e-Formulary ↗ (DIN 02204517)

Source record

DIN 02204517: Teva-Acebutolol Raw flags: chronicUseMed=Y, sec3=Y Item: 240400084; group id 272; item number 0562; lccId None; manufacturer id TEV Source form: Tab; strength: 100mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1871; ministry $0.1871 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02204517 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42996

Interchangeable products

Apo-Acebutolol · DIN 02147602 · $0.1871 Sectral · DIN 01926543 · not recorded

Shortage status: active shortage (reported 2026-03-10, last updated 2026-03-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02204517

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Acebutolol · DIN 02147610 · 200mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Apo-Acebutolol · DIN 02147610 Manufacturer: Apotex Inc.; listing date 1996-10-01 Daily cost (source): $0.5616 Health Canada: Marketed since 1995-12-31 · brand APO-ACEBUTOLOL · ATC C07AB04 ACEBUTOLOL · form Tablet · route Oral · ingredients ACEBUTOLOL (ACEBUTOLOL HYDROCHLORIDE) 200 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Acebutolol: Formulary list price $0.2808/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2808 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 02147610: Apo-Acebutolol Raw flags: chronicUseMed=Y, sec3=Y Item: 240400085; group id 272; item number 0563; lccId None; manufacturer id APX Source form: Tab; strength: 200mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2808; ministry $0.2808 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02147610 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17827

Interchangeable products

Sectral · DIN 01926551 · not recorded Teva-Acebutolol · DIN 02204525 · $0.2808

Shortage status: resolved shortage (ended 2024-09-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02147610

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Acebutolol · DIN 02204525 · 200mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Teva-Acebutolol · DIN 02204525 Manufacturer: Teva Canada Limited; listing date 1998-12-31 Daily cost (source): $0.5616 Health Canada: Marketed since 2011-01-25 · brand TEVA-ACEBUTOLOL · ATC C07AB04 ACEBUTOLOL · form Tablet · route Oral · ingredients ACEBUTOLOL (ACEBUTOLOL HYDROCHLORIDE) 200 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Teva-Acebutolol: Formulary list price $0.2808/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2808 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42997 · Verify on the e-Formulary ↗ (DIN 02204525)

Source record

DIN 02204525: Teva-Acebutolol Raw flags: chronicUseMed=Y, sec3=Y Item: 240400085; group id 272; item number 0563; lccId None; manufacturer id TEV Source form: Tab; strength: 200mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2808; ministry $0.2808 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02204525 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42997

Interchangeable products

Apo-Acebutolol · DIN 02147610 · $0.2808 Sectral · DIN 01926551 · not recorded

Shortage status: resolved shortage (ended 2022-01-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02204525

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Acebutolol · DIN 02147629 · 400mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Apo-Acebutolol · DIN 02147629 Manufacturer: Apotex Inc.; listing date 1996-10-01 Daily cost (source): $1.0696 Health Canada: Marketed since 1995-12-31 · brand APO-ACEBUTOLOL · ATC C07AB04 ACEBUTOLOL · form Tablet · route Oral · ingredients ACEBUTOLOL (ACEBUTOLOL HYDROCHLORIDE) 400 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Acebutolol: Formulary list price $0.5348/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5348 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 02147629: Apo-Acebutolol Raw flags: chronicUseMed=Y, sec3=Y Item: 240400116; group id 272; item number 0564; lccId None; manufacturer id APX Source form: Tab; strength: 400mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.5348; ministry $0.5348 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02147629 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17828

Interchangeable products

Sectral · DIN 01926578 · not recorded Teva-Acebutolol · DIN 02204533 · $0.5348

Shortage status: resolved shortage (ended 2024-09-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02147629

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Acebutolol · DIN 02204533 · 400mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Teva-Acebutolol · DIN 02204533 Manufacturer: Teva Canada Limited; listing date 1997-08-28 Daily cost (source): $1.0696 Health Canada: Marketed since 2011-01-25 · brand TEVA-ACEBUTOLOL · ATC C07AB04 ACEBUTOLOL · form Tablet · route Oral · ingredients ACEBUTOLOL (ACEBUTOLOL HYDROCHLORIDE) 400 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Teva-Acebutolol: Formulary list price $0.5348/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5348 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42998 · Verify on the e-Formulary ↗ (DIN 02204533)

Source record

DIN 02204533: Teva-Acebutolol Raw flags: chronicUseMed=Y, sec3=Y Item: 240400116; group id 272; item number 0564; lccId None; manufacturer id TEV Source form: Tab; strength: 400mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.5348; ministry $0.5348 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02204533 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42998

Interchangeable products

Apo-Acebutolol · DIN 02147629 · $0.5348 Sectral · DIN 01926578 · not recorded

Shortage status: active shortage (reported 2026-04-08, last updated 2026-04-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02204533

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sectral · DIN 01926543 · 100mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-10-02 — choose a marketed DIN from the same-category list.Discontinued 2018-10-02 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-10-02 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-10-02 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Sectral · DIN 01926543 Manufacturer: Sanofi Aventis Pharma; listing date 1996-10-01 Daily cost (source): $0.3742 Health Canada: Cancelled post market since 2018-10-02 · brand SECTRAL · ATC C07AB04 ACEBUTOLOL · form Tablet · route Oral · ingredients ACEBUTOLOL (ACEBUTOLOL HYDROCHLORIDE) 100 MG · company Sanofi-aventis canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Sectral: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12421 · Verify on the e-Formulary ↗ (DIN 01926543)

Source record

DIN 01926543: Sectral Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240400084; group id 272; item number 0562; lccId None; manufacturer id SAV Source form: Tab; strength: 100mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01926543 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12421

Interchangeable products

Apo-Acebutolol · DIN 02147602 · $0.1871 Teva-Acebutolol · DIN 02204517 · $0.1871

Shortage status: discontinued (2018-10-02, reported by SANOFI-AVENTIS CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926543

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2018-10-02 — choose a marketed DIN from the same-category list.

Sectral · DIN 01926551 · 200mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-08-09 — choose a marketed DIN from the same-category list.Discontinued 2018-08-09 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-08-09 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-08-09 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Sectral · DIN 01926551 Manufacturer: Sanofi Aventis Pharma; listing date 1996-10-01 Daily cost (source): $0.5616 Health Canada: Cancelled post market since 2018-08-09 · brand SECTRAL · ATC C07AB04 ACEBUTOLOL · form Tablet · route Oral · ingredients ACEBUTOLOL (ACEBUTOLOL HYDROCHLORIDE) 200 MG · company Sanofi-aventis canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Sectral: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12422 · Verify on the e-Formulary ↗ (DIN 01926551)

Source record

DIN 01926551: Sectral Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240400085; group id 272; item number 0563; lccId None; manufacturer id SAV Source form: Tab; strength: 200mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01926551 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12422

Interchangeable products

Apo-Acebutolol · DIN 02147610 · $0.2808 Teva-Acebutolol · DIN 02204525 · $0.2808

Shortage status: discontinued (2018-08-09, reported by SANOFI-AVENTIS CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926551

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2018-08-09 — choose a marketed DIN from the same-category list.

Sectral · DIN 01926578 · 400mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-03-30 — choose a marketed DIN from the same-category list.Discontinued 2017-03-30 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-03-30 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-03-30 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Sectral · DIN 01926578 Manufacturer: Sanofi Aventis Pharma; listing date 1996-10-01 Daily cost (source): $1.0696 Health Canada: Cancelled post market since 2017-03-30 · brand SECTRAL · ATC C07AB04 ACEBUTOLOL · form Tablet · route Oral · ingredients ACEBUTOLOL (ACEBUTOLOL HYDROCHLORIDE) 400 MG · company Sanofi-aventis canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Sectral: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12423 · Verify on the e-Formulary ↗ (DIN 01926578)

Source record

DIN 01926578: Sectral Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240400116; group id 272; item number 0564; lccId None; manufacturer id SAV Source form: Tab; strength: 400mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01926578 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12423

Interchangeable products

Apo-Acebutolol · DIN 02147629 · $0.5348 Teva-Acebutolol · DIN 02204533 · $0.5348

Shortage status: discontinued (2016-04-01, reported by SANOFI-AVENTIS CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926578

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2017-03-30 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary class (24:04 Cardiac Drugs) and how they are covered

Matched class: 24:04 Cardiac Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ATENOLOL, DIGOXIN, PROPAFENONE HCL Some products covered without a code (check the product listing): AMIODARONE HCL, AMLODIPINE, BISOPROLOL FUMARATE, DILTIAZEM HCL, DISOPYRAMIDE, FLECAINIDE ACETATE, METOPROLOL TARTRATE, MEXILETINE HCL, NADOLOL, NIFEDIPINE, PROPRANOLOL, SOTALOL HCL, TIMOLOL MALEATE, VERAPAMIL HCL 24:00 CARDIOVASCULAR DRUGS

RANOLAZINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:04 Cardiac Drugs

ATENOLOL

· 26 products · General benefit · strengths: 50mg, 100mg · Tab

BISOPROLOL FUMARATE

· 20 products · General benefit (18), Listed, not a benefit (2) · strengths: 1.25mg, 2.5mg, 5mg, 10mg · Tab

METOPROLOL TARTRATE

· 28 products · Listed, not a benefit (6), General benefit (22) · strengths: 100mg, 200mg, 50mg · LA Tab, Tab

NEBIVOLOL HYDROCHLORIDE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

NADOLOL

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 40mg, 80mg, 160mg · Tab

PROPRANOLOL

· 19 products · Off-Formulary Interchangeable, not an ODB benefit (8), General benefit (7), Listed, not a benefit (4) · strengths: 60mg, 80mg, 120mg, 160mg, 10mg, 20mg, 40mg · LA Cap, Tab

SOTALOL HCL

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 80mg, 160mg · Tab

TIMOLOL MALEATE

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CARVEDILOL

· 36 products · Listed, not a benefit (4), Limited Use, codes 183 (32) · strengths: 3.125mg, 6.25mg, 12.5mg, 25mg · Tab

AMIODARONE HCL

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 200mg · Tab

AMLODIPINE

· 56 products · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) · strengths: 1mg/mL, 2.5mg, 5mg, 10mg · Oral Sol, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:04 and 9 more

Full class listing Related classes: 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.

Other drugs whose Health Canada label lists a similar indication: hypertension

From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE AMLODIPINE · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) 1 INDICATIONS NORVASC (amlodipine besylate tablets) is indicated for: • Hypertension NORVASC is indicated in the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00071908.PDF; date AUG 02, 2023; DIN 00878928; fetched 2026-09-10 Product monograph AZILSARTAN MEDOXOMIL · Off-Formulary Interchangeable, not an ODB benefit 1 Part 1: Healthcare Professional Information Indications • EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) indicated for the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00082489.PDF; date 2025-10-24; DIN 02381389; fetched 2026-09-10 Product monograph BENAZEPRIL · Listed, not a benefit (3), General benefit (3) Indications BENAZEPRIL (benazepril hydrochloride tablets) is indicated for:  Treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00080887.PDF; date 2025-06-24; DIN 02273918; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL · General benefit • Heart Failure o The treatment of NYHA Class II and III heart failure with ejection fraction ≤ 40% in addition to standard therapy, with or without an ACE inhibitor. 1.1 Pediatrics Pediatrics (6 to 17 years of age): • Hypertension ATACAND is indicated for the treatment of essential hypertension in children and adolescents 6 to 17 years of age (see 7.1.3 Pediatrics, 14 CLINICAL TRIALS). PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph • Hypertension PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS ATACAND PLUS (candesartan cilexetil/hydrochlorothiazide) is indicated for: • the treatment of essential hypertension in patients for whom combination therapy is appropriate. PM: https://pdf.hres.ca/dpd_pm/00076288.PDF; date JUN 18, 2001; DIN 02244021; fetched 2026-09-10 Product monograph CHLORTHALIDONE · Listed, not a benefit (1), General benefit (2) 1 INDICATIONS APO-CHLORTHALIDONE (chlorthalidone) is indicated for: • Treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00069909.PDF; date MAR 14, 2023; DIN 00360279; fetched 2026-09-10 Product monograph CILAZAPRIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS INHIBACE PLUS (cilazapril and hydrochlorothiazide) is indicated for:  treatment of mild to moderate essential hypertension in patients for whom combination therapy with both cilazapril and hydrochlorothiazide is appropriate. PM: https://pdf.hres.ca/dpd_pm/00066994.PDF; date September 07, 1995; DIN 02181479; fetched 2026-09-10 Product monograph CLONIDINE HCL · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8) INDICATIONS AND CLINICAL USE TEVA-CLONIDINE (clonidine hydrochloride) is indicated for the treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00024986.PDF; date April 25, 2014; DIN 02046121; fetched 2026-09-10 Product monograph ENALAPRIL MALEATE & HYDROCHLOROTHIAZIDE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS VASERETIC® (enalapril and hydrochlorothiazide) is indicated for:  Treatment of essential hypertension in patients for whom this combination therapy with enalapril and hydrochlorothiazide is appropriate. PM: https://pdf.hres.ca/dpd_pm/00068096.PDF; date November 4, 2022; DIN 00657298; fetched 2026-09-10 Product monograph FELODIPINE · General benefit (10), Listed, not a benefit (2) 1 INDICATIONS PLENDIL (felodipine) is indicated for: • the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00082730.PDF; date 2025-12-09; DIN 00851779; fetched 2026-09-10 Product monograph and 20 more Coverage source: ON formulary extract 2026-08-26

What the Health Canada label says it is for

INDICATIONS AND CLINICAL USE APO-ACEBUTOLOL is indicated for the following:  Treatment of mild to moderate hypertension.  Long-term management of patients with angina pectoris due to ischemic heart disease. Treatment of mild to moderate hypertension: APO-ACEBUTOLOL is usually used in combination with other drugs, particularly a thiazide diuretic. However, it may be tried alone as an initial agent in those patients in whom, in the judgment of the physician, treatment should be started with a β-blocker rather than a diuretic. In patients with severe hypertension a β-adrenergic blocking agent may be used as part of a multiple drug regimen which would normally include a diuretic and a vasodilator. The combination of acebutolol with a diuretic or peripheral vasodilator has been found to be compatible and generally more effective than acebutolol alone. Limited experience with other antihypertensive agents has not shown evidence of incompatibility. APO-ACEBUTOLOL is not indicated in the emergency treatment of hypertensive crises. Geriatrics: Acebutolol has been used in the elderly without specific adjustment of dosage. APO-ACEBUTOLOL Product Monograph Page 3 of 34 Ho… https://pdf.hres.ca/dpd_pm/00047998.PDF PM date: October 24, 2018 Source product: APO-ACEBUTOLOL; DIN 02147602; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Teva-Acebutolol · DIN 02204517 Shortage status: active shortage (reported 2026-03-10, last updated 2026-03-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02204517

Check this DIN again

Teva-Acebutolol · DIN 02204533 Shortage status: active shortage (reported 2026-04-08, last updated 2026-04-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02204533

Check this DIN again

Sectral · DIN 01926543 Shortage status: discontinued (2018-10-02, reported by SANOFI-AVENTIS CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926543

Check this DIN again

Sectral · DIN 01926551 Shortage status: discontinued (2018-08-09, reported by SANOFI-AVENTIS CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926551

Check this DIN again

Sectral · DIN 01926578 Shortage status: discontinued (2016-04-01, reported by SANOFI-AVENTIS CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926578

Check this DIN again

Other review policies

For Sectral: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026